Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.
References
1.
GrantR.M., LamaJ.R., AndersonP.L.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.N Engl J Med2010; 363: 2587–2599.
2.
BaetenJ.M., DonnellD., NdaseP.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.N Engl J Med2012; 367: 399–410.
3.
McComseyG.A., TebasP., ShaneE.Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Clin Infect Dis2010; 51: 937–946.
4.
McComseyG.A., KitchD., DaarE.S.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.J Infect Dis2011; 203: 1791–1801.
5.
SaxP.E., WohlD., YinM.T.Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials.Lancet2015; 385: 2606–2615.
6.
FonnerV.A., DalglishS.L., KennedyC.E.Effectiveness and safety of oral HIV preexposure prophylaxis (PrEP) for all populations.AIDS2016; 30: 1973–1983.
7.
United States Public Health Service.Preexposure Prophylaxis for the Prevention of HIV in the United States - 2014. A Clinical Practice Guideline. (Updated 2014. Accessed 28 March 2017.) Available from https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.
8.
LiuA.Y., VittinghoffE., SellmeyerD.E.Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.PLoS One2011; 6: e23688.
9.
MulliganK., GliddenD.V., AndersonP.L.Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial.Clin Infect Dis2015; 61: 572–580.
10.
KasondeM., NiskaR.W., RoseC.Bone mineral density changes among HIV uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir emtricitabine or placebo in Botswana.PLoS One2014; 9: e90111.
11.
MirembeB.G., KellyC.W., MgodiN.Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis.J Acquir Immune Defic Syndr2016; 71: 287–294.
12.
GrantR., MulliganK., McMahanV.Recovery of bone mineral density after stopping oral HIV preexposure prophylaxis.Conference on Retroviruses and Opportunistic Infections. 22–25 February 2016, Boston, MA, USA. Abstract 48LB.
13.
ThigpenM.C., KebaabetsweP.M., PaxtonL.A.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.N Engl J Med2012; 367: 423–434.
14.
CooperC., CampionG., MeltonL.Hip fractures in the elderly: a world-wide projection.Osteoporos Int1992; 2: 285–289.
15.
CauleyJ.A., ChalhoubD., KassemA.M., Fuleihan GelH.Geographic and ethnic disparities in osteoporotic fractures.Nat Rev Endocrinol2014; 10: 338–351.
Castillo-MancillaJ.R., ZhengJ.H., RowerJ.E.Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.AIDS Res Hum Retroviruses2013; 29: 384–390.
18.
ThigpenM.C., KebaabetsweP.M., PaxtonL.A.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.N Engl J Med2012; 367: 423–434.
19.
BaetenJ.M., DonnellD., NdaseP.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.N Engl J Med2012; 367: 399–410.
20.
OfotokunI., TitanjiK., LahiriC.D.A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naive HIV-infected patients: a Phase IIb trial.Clin Infect Dis2016; 63: 663–671.
21.
OvertonE.T., ChanE.S., BrownT.T.Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial.Ann Intern Med2015; 162: 815–824.
GillespieL.D., RobertsonM.C., GillespieW.J.Interventions for preventing falls in older people living in the community.Cochrane Database Syst Rev2012; (9): CD007146.
24.
ClinicalTrials.gov. Safety and efficacy of emtricitabine and tenofovir alafenamide (F/TAF) fixed-dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at risk of HIV-1 infection. (DISCOVER). (Updated 6 March 2017. Accessed 28 March 2017.) Available from https://clinicaltrials.gov/ct2/show/NCT02842086.
